Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0090)
Name
Clioquinol
Synonyms
clioquinol; 130-26-7; 5-Chloro-7-iodoquinolin-8-ol; Iodochlorhydroxyquin; Chinoform; Chloroiodoquin; 5-Chloro-7-iodo-8-quinolinol; Chloroiodoquine; 5-Chloro-8-hydroxy-7-iodoquinoline; Vioform; Iodochloroxyquinoline; Cliquinol; Iodochlorohydroxyquinoline; Chlorojodochin; Enteroquinol; Iodochloroquine; Iodochloroxine; Iodoenterol; 7-Iodo-5-chloroxine; Entero-Vioform; Iodochlorhydroxyquinoline; 5-Chloro-7-iodo-8-hydroxyquinoline; Iodoxyquinoline; Alchloquin; Barquinol; Budoform; Cifoform; Dermaform; Dioquinol; Domeform; Eczecidin; Enteroseptol; Enterozol; Enterseptol; Entrokin; Iodenterol; Lekosept; Mycoquin; Quinambicide; Quinoform; Rheaform; Amebil; Amoenol; Bactol; Emaform; Nioform; Rometin; Entero-Bioform; Iodochlorohydroxyquin; Hi-Enterol; Iodochlorhydroxyquinol; Hydriodide-enterol; Quin-O-Creme; Chinoformum; Cliochinolum; Entero-Septol; Enterum locorten; 5-Chloro-7-iodo-quinolin-8-ol; Domeform-HC; 8-Quinolinol, 5-chloro-7-iodo-; 7-Iodo-5-chloro-8-hydroxyquinoline; Clioquinolum; Enterovalodon; Alioform; Chloro-8-hydroxyiodoquinoline; Enteritan; Jodchloroxychinolinum; Corque; Cortin; Oralcer; Iodo; Iodochloroxychinolinum; Cremo-quin; Entero-bio form; Entero-Vioformio; Ala-Quin; Quinoform (antiseptic); UAD Lotion; Vioform n.n.r.; Cliochinolo; Cliochinolo [DCIT]; Caswell No. 193; Formtone-HC; Clioquinolum [INN-Latin]; Quinoline, chloro-8-hydroxyiodo-; 5-Chlor-7-jod-8-hydroxy-chinolin; Rheaform boluses; iodochlorhydroxyquinolone; 5-Chlor-7-jod-8-hydroxy-chinolin [German]; NSC-3531; 7BHQ856EJ5; DTXSID7022837; CHEBI:74460; NSC-74938; NCGC00016391-05; CAS-130-26-7; TG2-36-2; C9H5ClINO; PBT-1; Quinoform (VAN); DTXCID502837; loquinol; Vioformio; Hi-eneterol; Iodochlorhydroxyquin Cream; Vioform-Hydrocortisone Mild; 22112-03-4; SMR000058282; Rheaform Boluses (Veterinary); CCRIS 6050; HSDB 6843; SR-01000002987; NSC 3531; EINECS 204-984-4; EPA Pesticide Chemical Code 024001; BRN 0153637; UNII-7BHQ856EJ5; Linolasept; Clioquinol [USP:INN:BAN]; Cloquinol; AI3-16451; Clioquinol (CQ); component of Hyquin; MFCD00006787; NSC 74938; Nystaform (Salt/Mix); Clioquinol (USP/INN); CLIOQUINOL [INN]; component of Formtone-HC; component of Heb-Cort V; Prestwick0_000886; Prestwick1_000886; Prestwick2_000886; Prestwick3_000886; CLIOQUINOL [HSDB]; Formtone-HC (Salt/Mix); CLIOQUINOL [VANDF]; CHEMBL497; EC 204-984-4; cid_2788; CLIOQUINOL [MART.]; SCHEMBL3967; CLIOQUINOL [USP-RS]; CLIOQUINOL [WHO-DD]; NCIOpen2_009062; Oprea1_438281; BSPBio_000672; BSPBio_002466; 5-21-03-00294 (Beilstein Handbook Reference); ksc-8-192; MLS000069389; MLS002454410; SPECTRUM1505114; SPBio_002891; BPBio1_000740; CLIOQUINOL [ORANGE BOOK]; component of Hyquin (Salt/Mix); BDBM32188; IODOCHLORHYDROXYQUIN [MI]; CLIOQUINOL [EP MONOGRAPH]; NSC3531; WLN: T66 BNJ GG II JQ; CLIOQUINOL [USP MONOGRAPH]; HMS1570B14; HMS1648J07; HMS2093I12; HMS2097B14; HMS2230I20; HMS3372J20; HMS3714B14; KUC105859N; Pharmakon1600-01505114; component of Cort-Quin (Salt/Mix); Tox21_110416; Tox21_200291; NSC759822; NYSTAFORM COMPONENT CLIOQUINOL; s4601; STK399761; 5-chloro-8-hydroxy-7-iodo-quinoline; component of Heb-Cort V (Salt/Mix); AKOS000120779; Tox21_110416_1; AC-6792; CCG-213339; DB04815; FD10468; NSC-759822; CLIOQUINOL COMPONENT OF NYSTAFORM; SMP1_000073; IODOCHLORHYDROXYQUIN [GREEN BOOK]; NCGC00016391-01; NCGC00016391-02; NCGC00016391-03; NCGC00016391-04; NCGC00016391-06; NCGC00016391-07; NCGC00016391-08; NCGC00016391-09; NCGC00016391-10; NCGC00016391-13; NCGC00021665-03; NCGC00021665-04; NCGC00021665-05; NCGC00257845-01; S4601 5-Chloro-8-hydroxy-7-iodoquin; AS-14597; BC167259; HY-14603; SBI-0206782.P001; AB00384254; FT-0603209; 4-stearylamino-phenyl-trimethylam. metilsulf.; EN300-20836; A16461; Clioquinol, VETRANAL(TM), analytical standard; component of Vioform-Hydrocortisone (Salt/Mix); D03538; AB00384254_17; 5-Chloro-7-iodo-8-quinolinol, >=95.0% (HPLC); CU-01000000767-2; Q-200875; Q5134338; SR-01000002987-2; SR-01000002987-3; SR-01000002987-4; BRD-K09255212-001-04-2; Z104483432; Clioquinol, British Pharmacopoeia (BP) Reference Standard; Clioquinol, European Pharmacopoeia (EP) Reference Standard; Clindamycin phosphate, Antibiotic for Culture Media Use Only; Clioquinol, United States Pharmacopeia (USP) Reference Standard; InChI=1/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13; CQL

    Click to Show/Hide
Structure
Formula
C9H5ClINO
IUPAC Name
5-chloro-7-iodoquinolin-8-ol
Canonical SMILES
C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1
InChI
InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
InChIKey
QCDFBFJGMNKBDO-UHFFFAOYSA-N
PubChem CID
2788
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 2 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Parkinson disease ICD-11: 8A00
 Disease Info 
Responsed Regulator RAC-alpha serine/threonine-protein kinase (AKT1) Suppressor
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
PI3K-Akt signaling pathway hsa04151
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model SK-N-SH cells Neuroblastoma Homo sapiens CVCL_0531
In Vivo Model
In total, twelve healthy adult rhesus monkeys (Macaca mulatta lasiotis, aged 4-5 years, and weighed 3.5-5 kg at the start of the study) were obtained from Sichuan Primed Biological Technology Co., Ltd. Monkeys were randomly divided into two groups: normal (control) group (n = 3) and MPTP group (n = 9). Monkeys from MPTP group were administered with MPTP by intramuscular injection daily at the beginning of the study, and then the MPTP dose was gradually added to 0.5 mg/kg at the end of the experiment. Monkeys from control group were injected with saline instead, and the other conditions were the same with MPTP group.

    Click to Show/Hide
Response regulation Ferroptosis was probably involved in the pathogenesis of parkinson's disease (PD). Clioquinol (CQ) can decrease the excessive iron in the SN to normal level and directly protect DA neurons against oxidative stress probably by activating the AKT/mTOR survival pathway and blocking p53-medicated cell death.
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Parkinson disease ICD-11: 8A00
 Disease Info 
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
PI3K-Akt signaling pathway hsa04151
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model SK-N-SH cells Neuroblastoma Homo sapiens CVCL_0531
In Vivo Model
In total, twelve healthy adult rhesus monkeys (Macaca mulatta lasiotis, aged 4-5 years, and weighed 3.5-5 kg at the start of the study) were obtained from Sichuan Primed Biological Technology Co., Ltd. Monkeys were randomly divided into two groups: normal (control) group (n = 3) and MPTP group (n = 9). Monkeys from MPTP group were administered with MPTP by intramuscular injection daily at the beginning of the study, and then the MPTP dose was gradually added to 0.5 mg/kg at the end of the experiment. Monkeys from control group were injected with saline instead, and the other conditions were the same with MPTP group.

    Click to Show/Hide
Response regulation Ferroptosis was probably involved in the pathogenesis of parkinson's disease (PD). Clioquinol (CQ) can decrease the excessive iron in the SN to normal level and directly protect DA neurons against oxidative stress probably by activating the AKT/mTOR survival pathway and blocking p53-medicated cell death.
References
Ref 1 Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway. Aging (Albany NY). 2020 May 18;12(10):9515-9533. doi: 10.18632/aging.103225. Epub 2020 May 18.